Skip to main content

Table 4 Secondary outcome measures during 6 months Of treatment with cineole or placebo for change of lung function and dyspnea symptoms *

From: Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: A placebo-controlled double-blind trial

LUNG FUNCTION AND SYMPTOMS

PLACEBO

CINEOLE

 
 

BASE LINE

3 MONTHS

6 MONTHS

BASE LINE

3 MONTHS

6 MONTHS

p-Value

FEV 1 [l]

1.61 ± 0.5

1.62 ± 0.5

1.61 ± 0.5

1.62 ± 0.5

1.67 ± 0.5

1.70 ± 0.6

0.0627

FVC [l]

2.23 ± 0.8

2.25 ± 0.8

2.22 ± 0.7

2.33 ± 0.8

2.36 ± 0.9

2.36 ± 0.9

0.2409

VC [l]

2.81 ± 0.8

2.71 ± 0.7

2.68 ± 0.8

2.80 ± 0.8

2.73 ± 0.8

2.72 ± 0.9

0.2060

Trouble in breathing #

1.8 ± 0.9

2.1 ± 0.9

2.2 ± 1.0

1.9 ± 0.9

2.4 ± 1.0

2.5 ± 1.1

0.0103&

Dyspnea in the morning $

1.1 ± 0.7

0.9 ± 0.7

0.7 ± 0.7

1.1 ± 0.8

0.7 ± 0.7

0.5 ± 0.6

0.0466&

Dyspnea at rest $

0.7 ± 0.7

0.4 ± 0.6

0.4 ± 0.6

0.6 ± 0.6

0.3 ± 0.5

0.3 ± 0.5

0.0156&

Dyspnea during exercise $

2.0 ± 0.6

1.8 ± 0.7

1.7 ± 0.8

2.0 ± 0.6

1.7 ± 0.7

1.5 ± 0.9

0.1252&

  1. * Plus – minus values are means ± SD. Higher scores on the symptoms-sum-score indicate more disease activity.
  2. P-Values are for the comparison of the changes from base line to 6 months between the two groups.
  3. &P-Values for the comparison are calculated by the multiple criteria calculation of 6 visits by Wei-Lachin between the two groups.
  4. # Scores: 0 = no day was good, 1 = 1–3 days were good, 2 = nearly every day was good, 3 = every day was good in a week.
  5. $ Scores: 0 = did not cause any problems, 1 = sometimes caused problems, 2 = caused a lot of problems, 3 = the most important problem the patient had